The Airways Disease Biology Research Group is dedicated to advancing our understanding of respiratory diseases through cutting-edge research in respiratory physiology, biomarkers, and molecular mechanisms. Led by Dr. Stephen Milne, a specialist in respiratory and sleep medicine, the group explores the biological underpinnings of diseases such as chronic obstructive pulmonary disease (COPD) and investigates novel diagnostic and therapeutic approaches.
Research Themes
- Respiratory Physiology: Investigating lung function and mechanisms of airway disease.
- Chronic Obstructive Pulmonary Disease (COPD): Understanding disease progression, phenotypes, and personalized treatment strategies.
- Biomarkers: Discovering and validating biomarkers to improve diagnosis, monitoring, and treatment efficacy in respiratory diseases.
Key Research Areas
- COPD:
- Identification of biomarkers to predict exacerbations and disease progression.
- Understanding the impact of systemic and airway epigenetic disruptions on health outcomes.
- Investigating the effects of inhaled corticosteroids on the airway microbiome.
- Post-COVID-19 Lung Disease:
- Examining the cellular landscape alterations in airway mucosa in long COVID.
- Systematic reviews and meta-analyses of pulmonary imaging and post-COVID-19 dyspnoea.
- Advanced Diagnostic Techniques:
- Development of novel physiological measurements and models for respiratory disease assessment.
- Integration of omics technologies for biomarker discovery.
Group Members
Group Members
- Stephen Milne
- Robert Robles